http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105111127-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 |
| filingDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105111127-B |
| titleOfInvention | Apremilast is amorphous and preparation method thereof |
| abstract | The present invention provides a kind of stable Apremilast without solvate is amorphous, the unbodied preparation method of Apremilast is also disclosed.It is confirmed by the methods of fusing point, X-ray powder diffraction figure (XRPD), infared spectrum (IR), differential scanning calorimetry (DSC) and thermal weight loss map (TG).The amorphous substantially pure, good fluidity, heap density are big, and apparent electrostatic phenomenon is not present.Compared with crystal form A, B, C, D, E, F and G of existing literature report, Apremilast of the invention is amorphous to temperature, illumination and moisture stable, is conducive to store for a long time；Solubility in water is big, is conducive to the absorption of drug, and bioavilability is high；Preparation method is easy to operate, and the recrystallisation solvent safety of use simultaneously is easy to remove, and is suitable for industrialized production. |
| priorityDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.